泰恩康：巴瑞替尼片获药品注册证书
T&KT&K(SZ:301263) Zhi Tong Cai Jing·2025-11-28 08:59

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the pharmaceutical sector [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the drug registration certificate for Baricitinib tablets [1] - Baricitinib is identified as a Janus kinase (JAK) inhibitor, which can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1]